Agenzia Italiana del Farmaco
VAXZEVRIA/COVID-19 Vaccine AstraZeneca: contraindication in individuals with previous capillary leak syndrome - VAXZEVRIA/COVID-19 Vaccine AstraZeneca: contraindication in individuals with previous capillary leak syndrome
VAXZEVRIA/COVID-19 Vaccine AstraZeneca: contraindication in individuals with previous capillary leak syndrome
The Italian Medicines Agency would like to inform you of the following:
- Very rare cases of capillary leak syndrome (CLS) have been reported in the first days after vaccination with Vaxzevria. A history of CLS was apparent in some of the cases. A fatal outcome has been reported.
- Vaxzevria is now contraindicated in individuals who have previously experienced episodes of CLS.
CLS is characterised by acute episodes of oedema mainly affecting the limbs, hypotension, haemoconcentration and hypoalbuminaemia. Patients with an acute episode of CLS following vaccination require prompt recognition and treatment. Intensive supportive therapy is usually warranted.
Published on: 23 June 2021
📆 Dalla prossima settimana unisciti a noi per la decima edizione della #MedSafetyWeek!
🌎 118 Paes...
Vai al post →
🤝 Incontro istituzionale tra il Presidente di #AIFA Robert Nisticò e il Capo dell’Autorità Egiziana...
Vai al post →
🤝 Ad Amsterdam l’incontro istituzionale tra #AIFA e Taiwan FDA.
📚 Durante il Summit 2025 della Co...
Vai al post →
Ciprofloxacina, levofloxacina, moxifloxacina: nomi forse poco familiari, ma che indicano una classe ...
Vai al post →
📊 Online il Rapporto AIFA 2024
La pubblicazione presenta i dati e le attività principali del 2024 a...
Vai al post →
🎗 #13ottobre - Questa sera #AIFA si illumina di rosa per la Giornata nazionale di sensibilizzazione...
Vai al post →
